Assess tamoxifen conversion to active endoxifen by CYP2D6 phenotype. Poor metabolizers have 75% lower endoxifen levels and reduced breast cancer protection.
Enter the values for the scenario you are assessing. Assess tamoxifen conversion to active endoxifen by CYP2D6 phenotype. Poor metabolizers have 75% lower endoxifen levels and reduced breast cancer protection. Use the tamoxifen cyp2d6 result to inform your calculation.